Geron Co. (NASDAQ:GERN) Given Average Recommendation of “Buy” by Brokerages

Geron Co. (NASDAQ:GERN) has been given an average rating of “Buy” by the eleven ratings firms that are covering the company, MarketBeat.com reports. One research analyst has rated the stock with a hold rating, nine have given a buy rating and one has issued a strong buy rating on the company. The average 12 month target price among brokerages that have covered the stock in the last year is $7.05.

GERN has been the topic of a number of recent analyst reports. StockNews.com raised Geron to a “sell” rating in a research report on Monday, August 5th. Scotiabank started coverage on Geron in a research report on Wednesday, October 16th. They set a “sector outperform” rating and a $6.00 target price on the stock. Needham & Company LLC reissued a “buy” rating and set a $6.00 price target on shares of Geron in a research report on Friday, August 9th. Leerink Partnrs raised Geron to a “strong-buy” rating in a research report on Monday, September 9th. Finally, Wedbush reissued an “outperform” rating and set a $8.00 price target on shares of Geron in a research report on Thursday, August 8th.

Institutional Trading of Geron

Large investors have recently made changes to their positions in the stock. National Bank of Canada FI boosted its stake in shares of Geron by 1,200.0% during the 2nd quarter. National Bank of Canada FI now owns 6,500 shares of the biopharmaceutical company’s stock worth $28,000 after acquiring an additional 6,000 shares in the last quarter. Crewe Advisors LLC lifted its position in shares of Geron by 870.0% during the 1st quarter. Crewe Advisors LLC now owns 9,700 shares of the biopharmaceutical company’s stock worth $32,000 after purchasing an additional 8,700 shares during the last quarter. Kingsview Wealth Management LLC acquired a new position in shares of Geron during the 1st quarter worth about $34,000. American Trust acquired a new position in shares of Geron during the 1st quarter worth about $38,000. Finally, Rovin Capital UT ADV acquired a new position in shares of Geron during the 3rd quarter worth about $62,000. Institutional investors own 73.71% of the company’s stock.

Geron Stock Up 1.2 %

GERN opened at $4.27 on Thursday. Geron has a one year low of $1.64 and a one year high of $5.34. The company has a debt-to-equity ratio of 0.12, a quick ratio of 3.60 and a current ratio of 3.61. The stock’s fifty day moving average is $4.33 and its 200-day moving average is $4.30. The company has a market capitalization of $2.57 billion, a PE ratio of -11.86 and a beta of 0.52.

Geron (NASDAQ:GERN) last announced its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.10). The company had revenue of $0.88 million for the quarter, compared to analyst estimates of $0.34 million. Geron had a negative return on equity of 73.79% and a negative net margin of 15,990.68%. Geron’s revenue for the quarter was up 2941.4% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.09) earnings per share. On average, equities analysts predict that Geron will post -0.34 EPS for the current fiscal year.

About Geron

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.